[Efficacy and safety analysis of interferon combined with imatinib in treating chronic myeloid leukemia].
Liu, Yang; Bao, Er-Ning; Zhong, Wen-Wen; Lu, Xue-Chun; Zhu, Hong-Li.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 22(2): 304-9, 2014 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-24762996
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage.
Successful management of imatinib despite alopecia and nail necrosis.
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.